NFG
REGN icon

Northbridge Financial Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Northbridge Financial Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$372K Sell
597
-138
-19% -$93.9K 0.14% 128
2026
Q1 		$549K Sell
735
-15
-2% -$11.5K 0.24% 94
2025
Q4 		$579K Buy
+750
New +$509K 0.26% 83

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Northbridge Financial Group's REGN Position: Q2 2026 in Review

Northbridge Financial Group reduced its Regeneron Pharmaceuticals (REGN) stake by 19% in Q2 2026, selling an estimated $93.9K and leaving 597 shares worth $372K. The position accounts for 0.14% of the portfolio, ranked #128.

Northbridge Financial Group first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $579K in Q4 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Northbridge Financial Group held 597 shares of Regeneron Pharmaceuticals worth $372K as of Q2 2026.
  • Northbridge Financial Group sold 138 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $93.9K.
  • Regeneron Pharmaceuticals made up 0.14% of Northbridge Financial Group's portfolio in Q2 2026, its #128 holding.
  • Northbridge Financial Group first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Northbridge Financial Group's Regeneron Pharmaceuticals position peaked at $579K in Q4 2025.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Northbridge Financial Group's 13F filing for Q2 2026, filed 9 Jul 2026.